In a study performed using cell lines from urothelial bladder cancer (BLCA), a tumour in which 50–70% of cases show activation of the PI3K/AKT/mTOR signalling [70], the pan-AKT inhibitor MK-2206 decreased cell viability in a number of cell lines. Here, AKT1 is linked to bladder transitional cell carcinoma.